comprehensive -WSS

comprehensive

author：entertainment 2025-08-23 08:57:46 - browse：6322

PHILADELPHIA — Novo Nordisk, which has dominated the diabetes and obesity markets with its blockbuster drugs Ozempic and Wegovy, now also wants to be a major player in heart disease.

The landmark Select trial presented over the weekend — which showed Wegovy significantly cut the risk of heart complications — is just one of many efforts by the Danish drugmaker to expand into the cardiovascular space. It’s also developing several treatments specific to heart disease and is acquiring a medication for high blood pressure.

“We have a clear vision of being an established cardiovascular company, just as we see ourselves as leaders in diabetes and obesity,” Martin Lange, Novo’s executive vice president of development, said in an interview here at the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： 7 more heat

entertainment

WSS

A letter from the executive editor: STAT UnitedHealth investigation

Vir antibody drug aimed at influenza A fails in clinical trial

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Texas Department of Public Safety speaks out on migrant abuse allegations

Medicare’s new pay boost for primary care is angering specialists

What is STAT's opinion section for?

focus

comprehensive

leisure time

State Dept. review finds Biden bears some blame for Afghanistan failures

Winning ticket for $1 billion Powerball jackpot sold in California

Malaria cases in Florida and Texas: Here’s what you need to know

Ventyx halts psoriasis drug development after lackluster trial results

In age of alternative facts, a scholarly course on calling out crap

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

Virginia high school admissions case could be legal follow

Awakening the world to the whoosh: A patient's crusade

State Dept. review finds Biden bears some blame for Afghanistan failures

I learned firsthand about improving diversity in clinical trials

explore

Divers poised to search for children washed away in Pennsylvania flash flood

Stanford president's case begs question: Who takes blame?

Tocagen's brain cancer gene therapy trial continues. Investors worry

Study identifies new proteins linked to dementia risk 25 years later

Ventyx halts psoriasis drug development after lackluster trial results

Medical school prerequisites are outdated

hotspot

entertainment

focus

hotspot